Desloratadine

ATC code

R06AX27

Therapeutic class

Antihistamine for systemic use · Other antihistamines for systemic use

Forms

oral tablet, oral solution, orodispersible tablet

Brand names

Dasselta (EU) · Aerius (ES) · Clarinex (US)

Overall confidence

high

Regulatory sources consulted

EMA EPAR EMEA/H/C/002310
AEMPS CIMA 00160065
https://www.ema.europa.eu/en/medicines/human/EPAR/dasselta
https://cima.aemps.es/cima/dochtml/ft/00160065/FT_00160065.html
AEMPS CIMA · nº registro 00160065 ↗
EMA EPAR · EMEA/H/C/002310 ↗
RxNorm rxcui 275635 ↗

Approved indications

Relief of symptoms associated with allergic rhinitis and urticaria.

Contraindications

Absolute

Hypersensitivity to the active substance, to any of the excipients, or to loratadine.

Clinical warnings

Should be administered with caution in patients with a medical or family history of seizures. — EMA SPC

Adverse events

Common (≥1%)

fatigue · dry mouth · headache

Rare but serious

hypersensitivity reactions · anaphylaxis · angioedema · seizures · tachycardia · palpitations · elevated liver enzymes

Pregnancy and lactation

Pregnancy: As a precautionary measure, it is preferable to avoid the use of desloratadine during pregnancy. Lactation: Desloratadine has been detected in breastfed newborns/infants of treated women. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.